3,379,064 Shares in Fate Therapeutics, Inc. $FATE Purchased by Johnson & Johnson

Posted by Brian Himes on Aug 16th, 2026

Johnson & Johnson purchased a new stake in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 3,379,064 shares of the biopharmaceutical company’s stock, valued at approximately $9,123,473,000. Fate Therapeutics accounts for about 1.1% of Johnson & Johnson’s portfolio, making the stock its 10th largest position.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its stake in shares of Fate Therapeutics by 73.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 28,676 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 12,114 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Fate Therapeutics by 161.2% during the fourth quarter. SG Americas Securities LLC now owns 38,913 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 24,013 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Fate Therapeutics by 20.0% during the third quarter. Bank of America Corp DE now owns 146,553 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 24,423 shares during the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Fate Therapeutics during the second quarter worth $28,000. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Fate Therapeutics during the fourth quarter worth $26,000. 97.54% of the stock is owned by hedge funds and other institutional investors.

Fate Therapeutics Stock Up 2.0%

Shares of FATE opened at $2.57 on Friday. Fate Therapeutics, Inc. has a 52-week low of $0.93 and a 52-week high of $3.23. The company has a 50-day simple moving average of $2.50 and a 200-day simple moving average of $1.86. The company has a market capitalization of $299.56 million, a PE ratio of -2.45 and a beta of 2.52.

Fate Therapeutics (NASDAQ:FATE – Get Free Report) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). Fate Therapeutics had a negative net margin of 1,941.09% and a negative return on equity of 60.87%. The company had revenue of $2.08 million for the quarter, compared to analyst estimates of $1.94 million. On average, research analysts anticipate that Fate Therapeutics, Inc. will post -1.04 EPS for the current year.

Wall Street Analysts Forecast Growth

FATE has been the topic of a number of analyst reports. Jefferies Financial Group set a $4.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, May 19th. Piper Sandler reiterated an “overweight” rating and set a $8.00 price target (up from $6.00) on shares of Fate Therapeutics in a research note on Friday. Wells Fargo & Company increased their price target on shares of Fate Therapeutics from $2.50 to $3.50 and gave the stock an “equal weight” rating in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a report on Monday, June 8th. Finally, Wedbush reiterated an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a research report on Friday. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $5.90.

Check Out Our Latest Analysis on FATE

Insider Buying and Selling at Fate Therapeutics

In related news, insider Cindy Tahl sold 25,590 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $1.88, for a total value of $48,109.20. Following the sale, the insider owned 628,155 shares in the company, valued at $1,180,931.40. This represents a 3.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.74% of the stock is currently owned by corporate insiders.

Fate Therapeutics Company Profile

(Free Report)

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.